Business Description
XOMA Royalty Corp
NAICS : 325412
SIC : 2834
ISIN : US98419J2069
Description
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.13 | |||||
| Equity-to-Asset | 0.38 | |||||
| Debt-to-Equity | 1.47 | |||||
| Debt-to-EBITDA | -3.14 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -6.29 | |||||
| Beneish M-Score | 864.89 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -45.4 | |||||
| 3-Year Book Growth Rate | 0.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 42.58 | |||||
| Future 3-5Y Total Revenue Growth Rate | 91.58 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 70.67 | |||||
| 9-Day RSI | 62.64 | |||||
| 14-Day RSI | 58.44 | |||||
| 6-1 Month Momentum % | 25.4 | |||||
| 12-1 Month Momentum % | 52.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.45 | |||||
| Quick Ratio | 9.45 | |||||
| Cash Ratio | 8.79 | |||||
| Days Sales Outstanding | 24.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.99 | |||||
| Forward Dividend Yield % | 7.97 | |||||
| 5-Year Yield-on-Cost % | 1.99 | |||||
| 3-Year Average Share Buyback Ratio | -0.8 | |||||
| Shareholder Yield % | -24.15 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -393.29 | |||||
| Net Margin % | -681.69 | |||||
| FCF Margin % | -313.16 | |||||
| ROE % | -39.48 | |||||
| ROA % | -23.66 | |||||
| ROIC % | -25.75 | |||||
| ROC (Joel Greenblatt) % | -21647.19 | |||||
| ROCE % | -25.35 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 53.35 | |||||
| PB Ratio | 3.82 | |||||
| Price-to-Tangible-Book | 3.82 | |||||
| EV-to-EBIT | -7.63 | |||||
| EV-to-Forward-EBIT | -30.29 | |||||
| EV-to-EBITDA | -7.77 | |||||
| EV-to-Forward-EBITDA | -30.29 | |||||
| EV-to-Revenue | 51.58 | |||||
| EV-to-Forward-Revenue | 17.26 | |||||
| EV-to-FCF | -16.31 | |||||
| Price-to-Median-PS-Value | 4.25 | |||||
| Price-to-Net-Current-Asset-Value | 32.14 | |||||
| Earnings Yield (Greenblatt) % | -13.11 | |||||
| FCF Yield % | -5.79 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers